Key result
Almitrine bismesylate increases PaO2 by ~6 mm Hg vs placebo in ventilated severe COPD patients.
Why the study?
Does almitrine bismesylate improve blood gases and ventilation-perfusion relationships in patients with severe COPD under mechanical ventilation?
RCT (n=18)
Randomly divided
Does almitrine bismesylate improve blood gases and ventilation-perfusion relationships in patients with severe COPD under mechanical ventilation?
Almitrine bismesylate improves the matching of pulmonary blood flow to ventilation and reduces gas exchange abnormalities in mechanically ventilated patients with severe COPD.
Answers are grounded in this paper and cite their sources.
Almitrine may aid acute hypoxemia management in ventilated severe COPD; confirms direct V/Q redistribution under controlled ventilation.
Although the respiratory stimulant effects of almitrine bismesylate (AB) via an action on the peripheral chemoreceptors have been demonstrated, the mechanism of its intrapulmonary action has not yet been elucidated. In order to abolish the stimulation of ventilation, observed in studies on spontaneously breathing patients, an investigation of patients suffering from severe COPD under constant mechanical ventilation, with FlO2= 0.21, during the weaning period was carried out. Eighteen patients were randomly divided into 2 groups (9 receiving 1.5 mg/kg AB and 9 receiving placebo). The ventilatory and hemodynamic variables, blood and alveolar gases, and the ratio distributions using the multiple inert gas technique were collected before treatment with drug or placebo, as well as 90 and 180 min afterwards. The PaO2 was found to be raised 90 min after AB administration (+5.7 ± 3.9 mm Hg, p < 0.01) and remained above the baseline value at 180 min (+5.4 ± 4.6 mm Hg, p < 0.01). Compared with those in the placebo group, these increases were significant (p < 0.01). A slight decrease in PaCO2 but similar in the 2 groups was observed despite constant ventilation. The hemodynamic data were the same for the 2 groups. The changes in overall criteria of the distributions (mean and SD) were small. The main finding was a decrease in the percentage of the perfusion flowing through the true shunt and the underventilated areas after AB treatment. In the control group, the blood flow percentage in the true shunt and low units was either stable or increased. The differences between the 2 groups were significant at the third hour for the shunt (p < 0.05) and at the ninetieth minute for the blood flow to = 0.1 (p < 0.02). Despite the ventilatory constraint, these changes, connected with stable , , and PAO2, confirm that AB improved the matching of pulmonary blood flow to ventilation, hence reducing gas exchange abnormalities in patients with COPD.
No takes yet. Share an insight, caveat, or question.
Castaing et al. (1986) conducted an RCT in Severe chronic obstructive pulmonary disease (COPD) (n=18). Almitrine bismesylate vs. Placebo was evaluated on PaO2 at 90 minutes (p=< 0.01). Almitrine bismesylate increased PaO2 at 90 minutes and 180 minutes compared to placebo in mechanically ventilated patients with severe COPD.
Synapse has enriched 10 related papers. Consider them for comparative context: